Exhibit 4.5


 


UNLESS THIS CERTIFICATE IS
PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (55
WATER STREET, NEW YORK, NEW YORK) (THE “DEPOSITARY”, WHICH TERM INCLUDES ANY
SUCCESSOR DEPOSITARY FOR THE CERTIFICATES) TO THE COMPANY OR ITS AGENT FOR
REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS
REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS REQUESTED BY
AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY (AND ANY PAYMENT HEREIN IS MADE
TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED
REPRESENTATIVE OF THE DEPOSITARY), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF
FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE
REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.


 


THE NOTE EVIDENCED HEREBY HAS
NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES
ACT”), OR ANY STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE
OFFERED OR SOLD EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE.  BY ITS ACQUISITION HEREOF, THE HOLDER (1)
REPRESENTS THAT IT IS A “QUALIFIED INSTITUTIONAL BUYER” (AS DEFINED
IN RULE 144A UNDER THE SECURITIES ACT); (2) AGREES THAT IT WILL NOT, PRIOR TO
EXPIRATION OF THE HOLDING PERIOD APPLICABLE TO SALES OF THIS NOTE UNDER RULE
144(K) UNDER THE SECURITIES ACT (OR ANY SUCCESSOR PROVISION), RESELL OR
OTHERWISE TRANSFER THIS NOTE OR THE COMMON STOCK ISSUABLE UPON CONVERSION OF
THIS NOTE EXCEPT (A) TO AMYLIN PHARMACEUTICALS, INC. OR ANY SUBSIDIARY THEREOF,
(B) TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE
SECURITIES ACT, (C) PURSUANT TO THE EXEMPTION FROM REGISTRATION PROVIDED BY
RULE 144 UNDER THE SECURITIES ACT (IF AVAILABLE) OR (D) PURSUANT TO A
REGISTRATION STATEMENT WHICH HAS BEEN DECLARED EFFECTIVE UNDER THE SECURITIES
ACT (AND WHICH CONTINUES TO BE EFFECTIVE AT THE TIME OF SUCH TRANSFER); (3)
PRIOR TO SUCH TRANSFER (OTHER THAN A TRANSFER PURSUANT TO CLAUSE  2(D) ABOVE), IT WILL FURNISH TO J.P. MORGAN
TRUST COMPANY, NATIONAL ASSOCIATION, AS TRUSTEE (OR A SUCCESSOR TRUSTEE, AS
APPLICABLE), SUCH CERTIFICATIONS, LEGAL OPINIONS OR OTHER INFORMATION AS THE
TRUSTEE MAY REASONABLY REQUIRE TO CONFIRM THAT SUCH TRANSFER IS BEING MADE
PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
REGISTRATION


 

















 


REQUIREMENTS OF THE SECURITIES
ACT; AND (4) AGREES THAT IT WILL DELIVER TO EACH PERSON TO WHOM THIS NOTE IS
TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND.  IN CONNECTION WITH ANY TRANSFER OF THIS NOTE
PRIOR TO THE EXPIRATION OF THE HOLDING PERIOD APPLICABLE TO SALES OF THIS NOTE
UNDER RULE 144(k) UNDER THE SECURITIES ACT (OR ANY SUCCESSOR PROVISION), THE
HOLDER MUST CHECK THE APPROPRIATE BOX SET FORTH ON THE REVERSE HEREOF RELATING
TO THE MANNER OF SUCH TRANSFER AND SUBMIT THIS CERTIFICATE TO J.P. MORGAN TRUST
COMPANY, NATIONAL ASSOCIATION, AS TRUSTEE (OR A SUCCESSOR TRUSTEE, AS
APPLICABLE).  THIS LEGEND WILL BE
REMOVED UPON THE EARLIER OF THE TRANSFER OF THE NOTE EVIDENCED HEREBY PURSUANT
TO CLAUSE 2(D) ABOVE OR UPON ANY TRANSFER OF THIS NOTE UNDER RULE 144 UNDER THE
SECURITIES ACT (OR ANY SUCCESSOR PROVISION). 
THE INDENTURE CONTAINS A PROVISION REQUIRING THE TRUSTEE TO REFUSE TO
REGISTER ANY TRANSFER OF THIS NOTE IN VIOLATION OF THE FOREGOING RESTRICTION.


 


2

















 


AMYLIN PHARMACEUTICALS, INC.


 


2.50% CONVERTIBLE SENIOR NOTE DUE 2011


 


	
   

  	
   

  	
  CUSIP:  032346AC2

  
	
   

  	
   

  	
   

  
	
  No. 1

  	
   

  	
  $200,000,000

  



 


Amylin
Pharmaceuticals, Inc., a corporation duly organized and validly existing under
the laws of the State of Delaware (herein called the “Company”, which term includes
any successor corporation under the Indenture referred to on the reverse
hereof), for value received hereby promises to pay to CEDE & CO. or its
registered assigns, the principal sum set forth on Schedule I hereto on April
15, 2011 at the office or agency of the Company maintained for that purpose in
accordance with the terms of the Indenture, in such coin or currency of the
United States of America as at the time of payment shall be legal tender for
the payment of public and private debts, and to pay interest, semiannually on
April 15 and October 15 of each year, commencing October 15, 2004, on said
principal sum, in like coin or currency, at the rate per annum of 2.50%, from
the date hereof.  Except as otherwise
provided in the Indenture, the interest payable on this Note pursuant to the
Indenture on any April 15 or October 15 will be paid to the Person
entitled thereto as it appears in the Note Register at the close of business on
the record date, which shall be the April 1 or October 1 (whether or not a
Business Day) next preceding such April 15 or October 15, as provided in the
Indenture;
provided that any such interest not punctually paid or duly provided
for shall be payable as provided in Section 6.01 of the Indenture.  Interest on the Notes shall be computed on
the basis of a 360-day year of twelve 30-day months.


 


The Company
shall pay interest (i) on any Notes in certificated form by check mailed to the
address of the Person entitled thereto as it appears in the Note Register (or,
upon written notice by such Person, by wire transfer in immediately available
funds, if such Person is entitled to interest on aggregate principal in excess
of $2.0 million) or (ii) on any Global Note by wire transfer of immediately
available funds to the account of the Depositary or its nominee.


 


The Company
promises to pay interest on overdue principal, premium, if any, and (to the
extent that payment of such interest is enforceable under applicable law)
interest and Liquidated Damages, if any, at the stated rate per annum of the
Notes.


 


Reference is
made to the further provisions of this Note set forth on the reverse hereof,
including, without limitation, provisions giving the holder of this Note the
right to convert this Note into Common Stock of the Company on the terms and
subject to the limitations referred to on the reverse hereof and as more fully
specified in the Indenture.  Such
further provisions shall for all purposes have the same effect as though fully
set forth at this place.


 


3

















 


This Note
shall be deemed to be a contract made under the laws of the State of New York,
and for all purposes shall be construed in accordance with and governed by the
laws of the State of New York, without regard to conflicts of laws principles
thereof.


 


This Note
shall not be valid or become obligatory for any purpose until the certificate
of authentication hereon shall have been manually signed by the Trustee or a
duly authorized authenticating agent under the Indenture.


 


4

















 


IN WITNESS
WHEREOF, the Company has caused this Note to be duly executed.


 


 


	
   

  	
  AMYLIN
  PHARMACEUTICALS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Lloyd A.
  Rowland

  
	
   

  	
   

  	
  Title:

  	
  Vice
  President, General Counsel and

  Secretary

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Mark G.
  Foletta

  
	
   

  	
   

  	
  Title:

  	
  Chief
  Financial Officer

  



 


5

















 


TRUSTEE’S CERTIFICATE OF AUTHENTICATION


 


This is one of the Notes
described in the within-named Indenture.


 


 


	
  Dated:

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  J.P. Morgan Trust Company, National
  Association,

  as Trustee

  	
   

  
	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
   

  
	
   

  	
  Authorized
  Signatory

  	
   

  
				



 


6

















 


FORM OF REVERSE OF NOTE


 


AMYLIN PHARMACEUTICALS, INC.


 


2.50% CONVERTIBLE SENIOR NOTE DUE 2011


 


This Note is
one of a duly authorized issue of Notes of the Company, designated as its 2.50%
Convertible Senior Notes due 2011 (herein called the “Notes”), limited in aggregate
principal amount to $175,000,000 (or if the Company sells an additional
$25,000,000 principal amount of its Notes pursuant to the option of the Initial
Purchasers granted pursuant to the Purchase Agreement dated as of March 31,
2004 between the Company and the Initial Purchasers, limited in the aggregate
principal amount to $200,000,000), issued and to be issued under and pursuant
to an Indenture dated as of April 6, 2004 (herein called the “Indenture”),
between the Company and J.P. Morgan Trust Company, National Association, as
trustee (herein called the “Trustee”), to which Indenture and all
indentures supplemental thereto reference is hereby made for a description of
the rights, limitations of rights, obligations, duties and immunities
thereunder of the Trustee, the Company and the holders of the Notes.


 


The Notes are
issuable in fully registered form, without coupons, in denominations of $1,000
principal amount and any multiple of $1,000. 
Upon due presentment for registration of transfer of this Note at the
office or agency of the Company maintained for that purpose in accordance with
the terms of the Indenture, a new Note or Notes of authorized denominations for
an equal aggregate principal amount will be issued to the transferee in
exchange thereof, subject to the limitations provided in the Indenture, without
charge except for any tax, assessment or other governmental charge imposed in
connection therewith.


 


The Notes are
not subject to redemption through the operation of any sinking fund and may not
be redeemed at the option of the Company prior to maturity other than pursuant
to Section 3.06 of the Indenture.


 


If a
Designated Event occurs at any time prior to maturity of the Notes, this Note
will be redeemable at the option of the holder of this Note at a redemption
price equal to 100% of the principal amount hereof, together with accrued
interest and Liquidated Damages, if any to (but excluding) the redemption date,
as provided in Article 3 of the Indenture.


 


At the
Company’s option (subject to the conditions set forth in the Indenture),
pursuant to the provisions of Section 3.02 of the Indenture, the Company may,
upon the occurrence of a Designated Event, pay the redemption price in the
Company’s Common Stock (or that of the Company’s parent, if applicable) or a
combination of cash and the applicable common stock.


 


Subject to
compliance with the provisions of the Indenture, prior to the close of business
on the final maturity date of the Notes, the holder hereof has the


 


7

















 


right, at its option, to convert each $1,000
principal amount of this Note into 29.1117 shares (the “Conversion Rate”) of the
Company’s Common Stock, as such shares shall be constituted at the date of
conversion and subject to adjustment from time to time as provided in the
Indenture.


 


No adjustment
in respect of interest on any Note converted or dividends on any shares issued
upon conversion of such Note will be made upon any conversion except as set
forth in the next sentence.  If this
Note (or portion hereof) is surrendered for conversion during the period from
the close of business on any record date for the payment of interest to the
close of business on the Business Day preceding the following interest payment
date, this Note (or portion hereof being converted) must be accompanied by
payment, in immediately available funds or other funds acceptable to the
Company, of an amount equal to the interest otherwise payable on such interest
payment date on the principal amount being converted; provided that no such payment
shall be required (1) if the Company has specified a redemption date following
a Designated Event that is after a record date and on or prior to the next
interest payment date or (2) to the extent of any overdue interest at the time
of conversion with respect to this Note.


 


No fractional
shares will be issued upon any conversion, but an adjustment and payment in
cash will be made, as provided in the Indenture, in respect of any fraction of
a share which would otherwise be issuable upon the surrender of any Note or
Notes for conversion.


 


A Note in
respect of which a holder is exercising its right to require redemption upon a
Designated Event may be converted up to the close of business on the business
day immediately preceding the applicable redemption date.


 


In case an
Event of Default shall have occurred and be continuing, the principal of,
premium, if any, and accrued interest, on all Notes may be declared by either
the Trustee or the holders of not less than 25% in aggregate principal amount
of the Notes then outstanding, and upon said declaration shall become, due and
payable, in the manner, with the effect and subject to the conditions provided
in the Indenture.


 


The Indenture
contains provisions permitting the Company and the Trustee, with the consent of
the holders of at least a majority in aggregate principal amount of the Notes
at the time outstanding, to execute supplemental indentures adding any
provisions to or changing in any manner or eliminating any of the provisions of
the Indenture or of any supplemental indenture or modifying in any manner the
rights of the holders of the Notes, subject to the exceptions set forth in
Section 10.02 of the Indenture.  Subject
to the provisions of the Indenture, the holders of a majority in aggregate
principal amount of the Notes at the time outstanding may on behalf of the
holders of all of the Notes waive any past, current or future breach of any
provision of the Indenture, default or Event of Default, in each case subject
to the exceptions set forth in the Indenture. 
Any such consent or waiver by the holder of this Note (unless revoked as
provided in


 


8

















 


the Indenture) shall be conclusive and
binding upon such holder and upon all future holders and owners of this Note
and any Notes which may be issued in exchange or substitution hereof,
irrespective of whether or not any notation thereof is made upon this Note or
such other Notes.


 


No reference
herein to the Indenture and no provision of this Note or of the Indenture shall
alter or impair the obligation of the Company, which is absolute and
unconditional, to pay the principal of and any premium and interest, on this
Note at the place, at the respective times, at the rate and in the coin or
currency herein prescribed.


 


The Company,
the Trustee, any authenticating agent, any paying agent, any conversion agent
and any Note Registrar may deem and treat the registered holder hereof as the
absolute owner of this Note (whether or not this Note shall be overdue and
notwithstanding any notation of ownership or other writing hereon made by
anyone other than the Company or any Note Registrar) for the purpose of
receiving payment hereof, or on account hereof, for the conversion hereof and
for all other purposes, and neither the Company nor the Trustee nor any other
authenticating agent nor any paying agent nor other conversion agent nor any
Note Registrar shall be affected by any notice to the contrary.  All payments made to or upon the order of
such registered holder shall, to the extent of the sum or sums paid, satisfy
and discharge liability for monies payable on this Note.


 


No recourse
for the payment of the principal of or any premium or interest on this Note, or
for any claim based hereon or otherwise in respect hereof, and no recourse
under or upon any obligation, covenant or agreement of the Company in the
Indenture or any supplemental indenture or in any Note, or because of the
creation of any indebtedness represented thereby, shall be had against any
incorporator, stockholder, employee, agent, officer or director or subsidiary,
as such, past, present or future, of the Company or of any successor
corporation, either directly or through the Company or any successor
corporation, whether by virtue of any constitution, statute or rule of law or
by the enforcement of any assessment or penalty or otherwise, all such
liability being, by acceptance hereof and as part of the consideration for the
issue hereof, expressly waived and released.


 


Terms used in
this Note and defined in the Indenture are used herein as therein defined.


 


9

















 


ABBREVIATIONS


 


The following
abbreviations, when used in the inscription of the face of this Note, shall be
construed as though they were written out in full according to applicable laws
or regulations.


 


	
  TEN COM -

  	
   

  	
  as tenants in common

  	
   

  	
  UNIF GIFT MIN ACT
  -        Custodian
           

  
	
  TEN ENT -

  	
   

  	
  as tenant by the
  entireties

  	
   

  	
  (Cust)     (Minor)

  
	
  JT TEN -

  	
   

  	
  as joint tenants with
  right of survivorship and not as tenants in common

  	
   

  	
  under Uniform Gifts to
  Minors Act 

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  (State)

  



 


Additional
abbreviations may also be used though not in the above list.


 


10

















 


CONVERSION NOTICE


 


	
  TO:

  	
   

  	
  AMYLIN
  PHARMACEUTICALS, INC.

  
	
   

  	
   

  	
  J.P. MORGAN
  TRUST COMPANY, NATIONAL ASSOCIATION

  



 


The
undersigned registered owner of this Note hereby irrevocably exercises the
option to convert this Note, or the portion thereof (which is $1,000 or a
multiple thereof) below designated, into shares of Common Stock of Amylin
Pharmaceuticals, Inc. in accordance with the terms of the Indenture referred to
in this Note, and directs that the shares issuable and deliverable upon such
conversion, together with any check in payment for fractional shares and any
Notes representing any unconverted principal amount hereof, be issued and
delivered to the registered holder hereof unless a different name has been
indicated below.  Capitalized terms used
herein but not defined shall have the meanings ascribed to such terms in the
Indenture.  If shares or any portion of
this Note not converted are to be issued in the name of a person other than the
undersigned, the undersigned will provide the appropriate information below and
pay all transfer taxes payable with respect thereto.  Any amount required to be paid by the undersigned on account of
interest accompanies this Note.


 


	
  Dated: 

  	
   

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Signature(s)

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Signature(s)
  must be guaranteed by an “eligible guarantor institution” meeting
  the requirements of the Note Registrar, which requirements include membership
  or participation in the Security Transfer Agent Medallion Program (“STAMP”)
  or such other “signature guarantee program” as may be determined by the
  Note Registrar in addition to, or in substitution for, STAMP, all in
  accordance with the Securities Exchange Act of 1934, as amended.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Signature
  Guarantee

  



 


Fill in the
registration of shares of Common Stock if to be issued, and Notes if to be
delivered, other than to and in the name of the registered holder:


 


11

















 


	
   

  	
   

  	
   

  
	
  (Name)

  	
   

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  (Street
  Address)

  	
   

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  (City, State
  and Zip Code)

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Please print
  name and address

  	
   

  
	
   

  	
   

  
	
  Principal
  amount to be converted

  	
   

  
	
   (if less than all):

  	
   

  
	
   

  	
   

  
	
  $

  	
   

  	
   

  	
   

  
	
   

  	
   

  
	
  Social Security
  or Other Taxpayer

  	
   

  
	
   Identification Number:

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
					



 


12

















 


OPTION TO ELECT REDEMPTION

UPON A DESIGNATED EVENT


 


	
  TO:

  	
   

  	
  AMYLIN
  PHARMACEUTICALS, INC.

  
	
   

  	
   

  	
  J.P. MORGAN
  TRUST COMPANY, NATIONAL ASSOCIATION

  



 


The
undersigned registered owner of this Note hereby irrevocably acknowledges
receipt of a notice from Amylin Pharmaceuticals, Inc. (the “Company”)
as to the occurrence of a Designated Event with respect to the Company and
requests and instructs the Company to redeem the entire principal amount of
this Note, or the portion thereof (which is $1,000 or a multiple thereof) below
designated, in accordance with the terms of the Indenture referred to in this
Note at the price of 100% of such entire principal amount or portion thereof,
together with accrued interest and Liquidated Damages, if any, to, but
excluding, the Designated Event Redemption Date, to the registered holder
hereof.  Capitalized terms used herein
but not defined shall have the meanings ascribed to such terms in the
Indenture.


 


 


	
  Dated: 

  	
   

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Signature(s)

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  NOTICE: The
  above signatures of the holder(s) hereof must correspond with the name as
  written upon the face of the Note in every particular without alteration or
  enlargement or any change whatever.

  
	
   

  	
   

  
	
   

  	
  Principal
  amount to be redeemed (if

  less than all):

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Social
  Security or Other Taxpayer

  Identification Number

  



 


13

















 


ASSIGNMENT


 


For value
received
                                                        
hereby sell(s) assign(s) and transfer(s) unto                                                         
(Please insert social security or other Taxpayer Identification Number of
assignee) the within Note, and hereby irrevocably constitutes and appoints
                                                        
attorney to transfer said Note on the books of the Company, with full power of
substitution in the premises.


 


In connection
with any transfer of the Note prior to the expiration of the holding period
applicable to sales thereof under Rule 144(k) under the Securities Act (or any
successor provision) (other than any transfer pursuant to a registration
statement that has been declared effective under the Securities Act), the undersigned
confirms that such Note is being transferred:


 


o                                    To
Amylin Pharmaceuticals, Inc. or a subsidiary thereof; or


 


o                                    To
a “qualified
institutional buyer” in compliance with Rule 144A under the
Securities Act of 1933, as amended; or


 


o                                    Pursuant
to and in compliance with Rule 144 under the Securities Act of 1933, as
amended; or


 


o                                    Pursuant
to a Registration Statement which has been declared effective under the
Securities Act of 1933, as amended, and which continues to be effective at the
time of transfer;


 


and unless the Note has been
transferred to Amylin Pharmaceuticals, Inc. or a subsidiary thereof, the
undersigned confirms that such Note is not being transferred to an “affiliate”
of the Company as defined in Rule 144 under the Securities Act of 1933, as
amended.


 


Unless one of the boxes is checked, the
Trustee will refuse to register any of the Notes evidenced by this certificate
in the name of any person other than the registered holder thereof.


 


	
  Dated: 

  	
   

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Signature(s)

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Signature(s)
  must be guaranteed by an “eligible guarantor institution” meeting
  the requirements of the Note

  



 


14

















 


	
   

  	
  Registrar,
  which requirements include membership or participation in the Security
  Transfer Agent Medallion Program (“STAMP”) or such other “signature
  guarantee program” as may be determined by the Note Registrar in
  addition to, or in substitution for, STAMP, all in accordance with the
  Securities Exchange Act of 1934, as amended.

  
	
   

  	
   

  
	
   

  	
  Signature
  Guarantee

  



 


NOTICE: The signature on the
Conversion Notice, the Option to Elect Redemption Upon a Designated Event, or
the Assignment must correspond with the name as written upon the face of the
Note in every particular without alteration or enlargement or any change
whatever.


 


15

















 


Schedule I


 


AMYLIN PHARMACEUTICALS, INC.


2.50% Convertible Senior Note due 2011


 


No.  1


 


 


	
  Date

  	
   

  	
  Principal Amount

  	
   

  	
  Notation Explaining Principal

  Amount Recorded

  	
   

  	
  Authorized Signature

  of Trustee or

  Custodian

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  



 


16